Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.
Takao
Toshitatsu
T
Kobayashi
Yutaka
Y
Kuroda
Junya
J
Omoto
Atsusi
A
Nishimura
Tomoko
T
Kamitsuji
Yuri
Y
Fukiya
Etsuko
E
Nakamura
Chie
C
Kimura
Shinya
S
Yoshikawa
Toshikazu
T
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001202:Ascitic Fluid / Q000166:cytology; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D019288:Herpesvirus 8, Human / Q000302:isolation & purification; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D010641:Phenotype; D010996:Pleural Effusion / Q000166:cytology; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab